Notably, isocitrate dehydrogenase 1 (IDH1) mutations occur in over 70% of WHO grade II–III gliomas. While patients with IDH1-mutant gliomas generally have better survival outcomes than those ...

The researchers developed a UR-ddPCR assay for the IDH1 R132H mutation that accurately measured ... ranging from >1,300 to <5 tumor cells/mm 2 within the core and at tumor margins, respectively.